AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$TRDA

MPM BIOVENTURES 2018, L.P. sold $617K of TRDA (indirect holdings)

MPM BIOVENTURES 2018, L.P. sold 86,482 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.14 ($7.06–$7.19, $0.62M total) across 3 trades over 2026-09-01 to 2026-09-03. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).

Original reporting
SEC EDGAR · MPM BIOVENTURES 2018, L.P., MPM BioVentures 2018 LLC, MPM BioVentures 2018 GP LLC
Published Sep 3, 2026, 11:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TRDA
Neutral
medium confidence
Mentioned
$TRDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRDANeutralLow
01

Why it matters

The sale represents a routine liquidity event with limited price impact.

02

Market read

The filing provides a fresh, primary‑source disclosure of an insider sale, but its modest size limits trading relevance.

03

What to watch

Potential upcoming dilution or financing activities could contextualize the sale, but none are disclosed.

Relevance 5/10Novelty 4/10Timing: filed 2026-09-03

Background

Entrada Therapeutics (TRDA) is a clinical‑stage biotech; insider transactions are regularly reported via Form 4.

Company-level read

Ticker impact

$TRDANeutralMedium confidence
Context

SEC Form 4 shows MPM BioVentures sold 86,482 shares of Entrada Therapeutics for $617,378.88.

Expected impact

Limited short-term price pressure; likely negligible impact on stock.

Evidence & confidence

A $617k sale by a 10% owner is a routine liquidity event; no material change in control or valuation.

Market effects

Sector

Minimal effect on biotech sector; insider sales are common and not sector‑wide drivers.

Regional

No regional impact beyond the company's own share activity.

Global

Limited global relevance; only affects Entrada Therapeutics investors.

Counterpoint

What could challenge this read

Some traders may view any insider sell as a bearish signal, but the modest size suggests no strong conviction.

Key entities

  • Company
    Entrada Therapeutics, Inc.

    Issuer of the securities sold.

  • Insider
    MPM BioVentures 2018, L.P.

    Reporter of the transaction, 10% owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TRDA insider trading history →

Related articles

OCT 14
$TRDAMed

Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level

Entrada Therapeutics (TRDA) will test its Duchenne muscular dystrophy therapy, ENTR-601-44, at the highest planned dose (18 mg/kg) in its Phase 1/2 study after a favorable safety review. The study aims to evaluate safety, tolerability, and effectiveness in patients aged 4 to 20. Data from earlier cohorts are expected by the end of 2026 and early 2027.

rttnews.com1 min
OCT 14
$TRDAMedAI 9/10

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201…

Entrada Therapeutics, Inc. (TRDA) filed an SEC Form 8-K — Other Events. Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 -- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 m

SEC EDGAR 8-K2 min
OCT 14
$TRDAMedAI 8/10

Entrada reports phase 1/2 trial data for DMD therapy candidate

Entrada Therapeutics (TRDA) reported positive phase 1/2 trial data for ENTR-601-45 in Duchenne muscular dystrophy patients. The study met safety and tolerability goals, with treated patients showing increased dystrophin and exon skipping. Adverse events were mild. Cohort 2 data is expected in 2027. The company plans higher doses in subsequent cohorts.

investing.com2 min
OCT 14
$TRDAMedAI 8/10

Entrada receives clearance to test highest dose in DMD trial

Entrada Therapeutics (TRDA) advanced to the highest dose in its DMD trial after positive safety and pharmacokinetic data. The Phase 1/2 study, ELEVATE-44-201, is evaluating ENTR-601-44 for Duchenne muscular dystrophy. The company expects data from Cohort 1 by year-end 2026 and Cohort 2 in Q1 2027. ENTR-601-44 targets 8% of the global DMD patient population and received FDA Rare Pediatric Disease Designation in December 2025.

investing.com2 min